Cargando…

Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus

SIMPLE SUMMARY: Barrett’s esophagus (BE) is the precursor of esophageal adenocarcinoma (EAC). Dysplastic BE (DBE), including low-grade dysplasia (LGD) and high-grade dysplasia (HGD), shows a higher progression risk to EAC compared to non-dysplastic BE (NDBE). If LGD or HGD is detected, more intensiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiaojuan, Gabriëls, Ruben Y., Hooghiemstra, Wouter T. R., Koller, Marjory, Meersma, Gert Jan, Buist-Homan, Manon, Visser, Lydia, Robinson, Dominic J., Tenditnaya, Anna, Gorpas, Dimitris, Ntziachristos, Vasilis, Karrenbeld, Arend, Kats-Ugurlu, Gursah, Fehrmann, Rudolf S. N., Nagengast, Wouter B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139936/
https://www.ncbi.nlm.nih.gov/pubmed/35626066
http://dx.doi.org/10.3390/cancers14102462
_version_ 1784714977433616384
author Zhao, Xiaojuan
Gabriëls, Ruben Y.
Hooghiemstra, Wouter T. R.
Koller, Marjory
Meersma, Gert Jan
Buist-Homan, Manon
Visser, Lydia
Robinson, Dominic J.
Tenditnaya, Anna
Gorpas, Dimitris
Ntziachristos, Vasilis
Karrenbeld, Arend
Kats-Ugurlu, Gursah
Fehrmann, Rudolf S. N.
Nagengast, Wouter B.
author_facet Zhao, Xiaojuan
Gabriëls, Ruben Y.
Hooghiemstra, Wouter T. R.
Koller, Marjory
Meersma, Gert Jan
Buist-Homan, Manon
Visser, Lydia
Robinson, Dominic J.
Tenditnaya, Anna
Gorpas, Dimitris
Ntziachristos, Vasilis
Karrenbeld, Arend
Kats-Ugurlu, Gursah
Fehrmann, Rudolf S. N.
Nagengast, Wouter B.
author_sort Zhao, Xiaojuan
collection PubMed
description SIMPLE SUMMARY: Barrett’s esophagus (BE) is the precursor of esophageal adenocarcinoma (EAC). Dysplastic BE (DBE), including low-grade dysplasia (LGD) and high-grade dysplasia (HGD), shows a higher progression risk to EAC compared to non-dysplastic BE (NDBE). If LGD or HGD is detected, more intensive endoscopic surveillance or endoscopic treatment is recommended. This results in a significantly improved prognosis compared to EACs treated by surgery and/or chemoradiotherapy. However, the miss rates for detecting DBE by endoscopy remain high. Fluorescence molecular endoscopy (FME) can fill this gap by targeting the tumor-specific expression of proteins. This study aimed to identify target proteins suitable for FME. We identified SPARC, SULF1, PKCι, and DDR1 as promising imaging targets for FME to differentiate DBE from NDBE tissue. We are also the first to develop near-infrared fluorescent tracers, SULF1-800CW and SPARC-800CW, for the endoscopic imaging of DBE tissue. ABSTRACT: Barrett’s esophagus (BE) is the precursor of esophageal adenocarcinoma (EAC). Dysplastic BE (DBE) has a higher progression risk to EAC compared to non-dysplastic BE (NDBE). However, the miss rates for the endoscopic detection of DBE remain high. Fluorescence molecular endoscopy (FME) can detect DBE and mucosal EAC by highlighting the tumor-specific expression of proteins. This study aimed to identify target proteins suitable for FME. Publicly available RNA expression profiles of EAC and NDBE were corrected by functional genomic mRNA (FGmRNA) profiling. Following a class comparison between FGmRNA profiles of EAC and NDBE, predicted, significantly upregulated genes in EAC were prioritized by a literature search. Protein expression of prioritized genes was validated by immunohistochemistry (IHC) on DBE and NDBE tissues. Near-infrared fluorescent tracers targeting the proteins were developed and evaluated ex vivo on fresh human specimens. In total, 1976 overexpressed genes were identified in EAC (n = 64) compared to NDBE (n = 66) at RNA level. Prioritization and IHC validation revealed SPARC, SULF1, PKCι, and DDR1 (all p < 0.0001) as the most attractive imaging protein targets for DBE detection. Newly developed tracers SULF1-800CW and SPARC-800CW both showed higher fluorescence intensity in DBE tissue compared to paired non-dysplastic tissue. This study identified SPARC, SULF1, PKCι, and DDR1 as promising targets for FME to differentiate DBE from NDBE tissue, for which SULF1-800CW and SPARC-800CW were successfully ex vivo evaluated. Clinical studies should further validate these findings.
format Online
Article
Text
id pubmed-9139936
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91399362022-05-28 Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus Zhao, Xiaojuan Gabriëls, Ruben Y. Hooghiemstra, Wouter T. R. Koller, Marjory Meersma, Gert Jan Buist-Homan, Manon Visser, Lydia Robinson, Dominic J. Tenditnaya, Anna Gorpas, Dimitris Ntziachristos, Vasilis Karrenbeld, Arend Kats-Ugurlu, Gursah Fehrmann, Rudolf S. N. Nagengast, Wouter B. Cancers (Basel) Article SIMPLE SUMMARY: Barrett’s esophagus (BE) is the precursor of esophageal adenocarcinoma (EAC). Dysplastic BE (DBE), including low-grade dysplasia (LGD) and high-grade dysplasia (HGD), shows a higher progression risk to EAC compared to non-dysplastic BE (NDBE). If LGD or HGD is detected, more intensive endoscopic surveillance or endoscopic treatment is recommended. This results in a significantly improved prognosis compared to EACs treated by surgery and/or chemoradiotherapy. However, the miss rates for detecting DBE by endoscopy remain high. Fluorescence molecular endoscopy (FME) can fill this gap by targeting the tumor-specific expression of proteins. This study aimed to identify target proteins suitable for FME. We identified SPARC, SULF1, PKCι, and DDR1 as promising imaging targets for FME to differentiate DBE from NDBE tissue. We are also the first to develop near-infrared fluorescent tracers, SULF1-800CW and SPARC-800CW, for the endoscopic imaging of DBE tissue. ABSTRACT: Barrett’s esophagus (BE) is the precursor of esophageal adenocarcinoma (EAC). Dysplastic BE (DBE) has a higher progression risk to EAC compared to non-dysplastic BE (NDBE). However, the miss rates for the endoscopic detection of DBE remain high. Fluorescence molecular endoscopy (FME) can detect DBE and mucosal EAC by highlighting the tumor-specific expression of proteins. This study aimed to identify target proteins suitable for FME. Publicly available RNA expression profiles of EAC and NDBE were corrected by functional genomic mRNA (FGmRNA) profiling. Following a class comparison between FGmRNA profiles of EAC and NDBE, predicted, significantly upregulated genes in EAC were prioritized by a literature search. Protein expression of prioritized genes was validated by immunohistochemistry (IHC) on DBE and NDBE tissues. Near-infrared fluorescent tracers targeting the proteins were developed and evaluated ex vivo on fresh human specimens. In total, 1976 overexpressed genes were identified in EAC (n = 64) compared to NDBE (n = 66) at RNA level. Prioritization and IHC validation revealed SPARC, SULF1, PKCι, and DDR1 (all p < 0.0001) as the most attractive imaging protein targets for DBE detection. Newly developed tracers SULF1-800CW and SPARC-800CW both showed higher fluorescence intensity in DBE tissue compared to paired non-dysplastic tissue. This study identified SPARC, SULF1, PKCι, and DDR1 as promising targets for FME to differentiate DBE from NDBE tissue, for which SULF1-800CW and SPARC-800CW were successfully ex vivo evaluated. Clinical studies should further validate these findings. MDPI 2022-05-17 /pmc/articles/PMC9139936/ /pubmed/35626066 http://dx.doi.org/10.3390/cancers14102462 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhao, Xiaojuan
Gabriëls, Ruben Y.
Hooghiemstra, Wouter T. R.
Koller, Marjory
Meersma, Gert Jan
Buist-Homan, Manon
Visser, Lydia
Robinson, Dominic J.
Tenditnaya, Anna
Gorpas, Dimitris
Ntziachristos, Vasilis
Karrenbeld, Arend
Kats-Ugurlu, Gursah
Fehrmann, Rudolf S. N.
Nagengast, Wouter B.
Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus
title Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus
title_full Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus
title_fullStr Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus
title_full_unstemmed Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus
title_short Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus
title_sort validation of novel molecular imaging targets identified by functional genomic mrna profiling to detect dysplasia in barrett’s esophagus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139936/
https://www.ncbi.nlm.nih.gov/pubmed/35626066
http://dx.doi.org/10.3390/cancers14102462
work_keys_str_mv AT zhaoxiaojuan validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT gabrielsrubeny validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT hooghiemstrawoutertr validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT kollermarjory validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT meersmagertjan validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT buisthomanmanon validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT visserlydia validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT robinsondominicj validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT tenditnayaanna validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT gorpasdimitris validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT ntziachristosvasilis validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT karrenbeldarend validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT katsugurlugursah validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT fehrmannrudolfsn validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus
AT nagengastwouterb validationofnovelmolecularimagingtargetsidentifiedbyfunctionalgenomicmrnaprofilingtodetectdysplasiainbarrettsesophagus